Group 2—Intermediate epilepsy/metabolic disorders (Ion-channel and neuronal-excitability phenotype): This group comprised patients harboring variants in SCN2A, PAH, IQSEC2, and GNPAT. This evidence concerns the gene PAH and epilepsy.